|
It should be noted that, per the gore® excluder® aaa endoprosthesis instructions for use (ifu), adverse events that may occur and/or require intervention include but are not limited to aneurysm enlargement.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
The field sales associate (fsa) reported the following to gore: on (b)(6) 2018, the patient underwent an endovascular procedure utilizing the gore® excluder® aaa endoprostheses.The patient tolerated the procedure.On (b)(6) 2025, the patient underwent a reintervention procedure utilizing the gore® excluder® aaa endoprosthesis (contralateral leg) and the gore® excluder® conformable aaa endoprosthesis with active control system (aortic extender) in zone 9 due to aneurysm enlargement.The aneurysm grew to about 2.5 cm.The patient tolerated the procedure.The cause of the enlargement is disease progression.
|